A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male Participants

A Phase 1, Open-Label, Two-Part Study of the Disposition and Absolute Bioavailability of [14C]-LY3473329 in Healthy Male Participants

The main purpose of this study is to evaluate how much of the study drug (LY3473329), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy male participants. The study will also measure how much of the study drug gets into the bloodstream when taken orally, compared to when injected directly into the vein, how its broken down, and how long it takes the body to get rid of it. The study is conducted in two parts. The study will last up to approximately 9 and 7 weeks for part 1 and 2, respectively.

Inclusion Criteria:

• Male participants who are overtly healthy as determined by medical evaluation
• Have a body mass index of 18.0 to 35.0 kilograms per meter squared (kg/m²), inclusive
• Males who agree to use highly effective or effective methods of contraception

Exclusion Criteria:

• Have known allergies to LY3473329, related compounds, or any components of the formulation, or history of significant atopy
• Have a history of constipation or have had acute constipation within 3 weeks prior to check-in
• Have participated in any clinical study involving a radiolabeled investigational product within 12 months prior to check-in. Any previous radiolabeled study intervention must have been received more than 12 months prior to check-in
• Have used or plan to use over-the-counter or prescription medication within 14 days prior to dosing, or any medications or products known to alter drug absorption, metabolism, or elimination processes
• Have participated, within the last 3 months, in a clinical study involving an investigational product